GSK RSV shot 43% effective against severe disease in third year
WEB1 day ago · Oct 8 (Reuters) - GSK (GSK.L) said on Tuesday that its Arexvy respiratory syncytial virus vaccine was 43.3% effective in preventing severe illness in its third season after patients received the ...
GSK agrees to settle about 80,000 Zantac lawsuits for up to $2.2
WEB4 hours ago · CNN —. GSK has agreed to pay up to $2.2 billion to settle most lawsuits in US state courts claiming that a discontinued version of the heartburn drug Zantac caused cancer, the company announced ...
Zantac’s Developer Settles Lawsuits Claiming Cancer Link
WEB3 hours ago · By Rebecca Robbins. Oct. 9, 2024, 8:05 p.m. ET. The British drug maker GSK said on Wednesday that it would pay up to $2.2 billion to settle most of the lawsuits filed against it by people who ...
GSK to Settle 80,000 Zantac Cases for Up to $2.2 Billion
WEB10 hours ago · GSK Plc said it will pay as much as $2.2 billion to resolve about 80,000 US court cases related to contamination of its Zantac reflux medication with a suspected carcinogen.
Press releases - GSK
WEBBrowse GSK global press releases issued since 2009. Search them by keyword or browse by year/business category. Press releases issued by our local operating companies can be viewed on our market websites.
GSK Says RSV Vaccine Offers Protection Over Three Seasons
WEB1 day ago · 1:42. GSK Plc’s shot for respiratory syncytial virus provided protection across three seasons after vaccination, the company said Tuesday. The shot for older adults showed cumulative efficacy ...
Press releases | GSK US
WEBUS FDA approves expanded age indication for GSK’s AREXVY, the first respiratory syncytial virus (RSV) vaccine for adults aged 50-59 at increased risk.
US FDA approves GSK’s AREXVY, the world’s first respiratory …
WEBMay 3, 2023 · GSK plc (LSE/NYSE: GSK) today announced that the US Food and Drug Administration (FDA) has approved AREXVY (respiratory syncytial virus vaccine, adjuvanted) for the prevention of lower respiratory tract disease (LRTD) caused by respiratory syncytial virus (RSV) in individuals 60 years of age and older. This is the first RSV vaccine for older ...
Jemperli (dostarlimab-gxly) plus chemotherapy approved in the US ... - GSK
WEBJul 31, 2023 · GSK plc (LSE/NYSE: GSK) today announced that the US Food and Drug Administration (FDA) has approved Jemperli (dostarlimab-gxly) in combination with carboplatin and paclitaxel, followed by Jemperli as a single agent for the treatment of adult patients with primary advanced or recurrent endometrial cancer that is mismatch repair deficient (dMMR ...
GSK delivers strong 2022 performance with full year sales of £29.3 ...
WEBFeb 1, 2023 · Step change in commercial execution drives strong sales growth across Specialty Medicines and Vaccines. Sales of £29.3 billion +19% AER, +13% CER. Sales +15% AER, +10% CER excluding COVID-19 solutions.